Cargando…

经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析

BACKGROUND AND OBJECTIVE: Transcatheter arterial chemotherapy and embolization is the main method in the treatment of lung cancer, but most of the reports do not study individually to small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), hypovascular and hypervascular lung cancer. The p...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000702/
https://www.ncbi.nlm.nih.gov/pubmed/20677656
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.05.29
_version_ 1783331819878350848
collection PubMed
description BACKGROUND AND OBJECTIVE: Transcatheter arterial chemotherapy and embolization is the main method in the treatment of lung cancer, but most of the reports do not study individually to small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), hypovascular and hypervascular lung cancer. The pre-embolization perfusion of hemotherapeutics is still being used routinely and seldom report to iodized oil embolization. The article summarized the quality of life after the treatment, clinical efficiency, survival time and complications to evaluate the clinical effect of primary hypervascular NSCLC treated with embolization of emulsion of chemotherapeutics and iodized oil. METHODS: The study totally analyzed 41 cases which confirmed by pathology and follow up study from January, 2008 to January 2009. The CT scan with Ⅳ contrast demonstrates over moderate enhanced lesion which indicate hypervascular. Within the 41 cases, 23 cases of central, 18 cases of peripheral. Suqamous carcinoma 21 cases, adenocarcinoma 15 cases and squamoadenocarcinoma 5 cases. Stage Ⅲb 34 cases, stage Ⅳ 7 cases. Superselective incubation with microcatheter under DSA, to embolize the capillary bed with liquefied iodized oil and the emulsion of pharmorubicin, to embolize the supply artery of the tumor with gelatin foam microparticle. The liquefied iodized oil 5 mL-10 mL, pharmorubicin 10 mg-30 mg. The longest follow up is 12 months and to compare with the references of 2007-2009. RESULTS: The KPS is widely acclaimed after the treatment (P < 0.05), no complete response (CR), 31 cases of partial response (PR), 7 cases of no change (NC) and 3 cases of progressive disease (PD), the total efficiency (CR+PR) is 75.6%. The clinical efficiency (CR+PR+NC) is 92.68%. 33 cases of total survival tome over 12 months (80.48%), Ⅲb stage 29/34 (85.29%), Ⅳ stage 4/7 (57.14%). 1 case with severe complication-spinal injury. CONCLUSION: To treat primary hypervascular NSCLC with simple embolization of emulsion of chemotherapeutics and iodized oil is very useful and can avoid the side effect of chemotherapeutics. The key point to avoid spinal injury and other severe complications is to distinguish the spinal aretery and intratumor AV fistula by using superselective incubation with microcatheter under DSA.
format Online
Article
Text
id pubmed-6000702
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60007022018-07-06 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析 Zhongguo Fei Ai Za Zhi 临床经验 BACKGROUND AND OBJECTIVE: Transcatheter arterial chemotherapy and embolization is the main method in the treatment of lung cancer, but most of the reports do not study individually to small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), hypovascular and hypervascular lung cancer. The pre-embolization perfusion of hemotherapeutics is still being used routinely and seldom report to iodized oil embolization. The article summarized the quality of life after the treatment, clinical efficiency, survival time and complications to evaluate the clinical effect of primary hypervascular NSCLC treated with embolization of emulsion of chemotherapeutics and iodized oil. METHODS: The study totally analyzed 41 cases which confirmed by pathology and follow up study from January, 2008 to January 2009. The CT scan with Ⅳ contrast demonstrates over moderate enhanced lesion which indicate hypervascular. Within the 41 cases, 23 cases of central, 18 cases of peripheral. Suqamous carcinoma 21 cases, adenocarcinoma 15 cases and squamoadenocarcinoma 5 cases. Stage Ⅲb 34 cases, stage Ⅳ 7 cases. Superselective incubation with microcatheter under DSA, to embolize the capillary bed with liquefied iodized oil and the emulsion of pharmorubicin, to embolize the supply artery of the tumor with gelatin foam microparticle. The liquefied iodized oil 5 mL-10 mL, pharmorubicin 10 mg-30 mg. The longest follow up is 12 months and to compare with the references of 2007-2009. RESULTS: The KPS is widely acclaimed after the treatment (P < 0.05), no complete response (CR), 31 cases of partial response (PR), 7 cases of no change (NC) and 3 cases of progressive disease (PD), the total efficiency (CR+PR) is 75.6%. The clinical efficiency (CR+PR+NC) is 92.68%. 33 cases of total survival tome over 12 months (80.48%), Ⅲb stage 29/34 (85.29%), Ⅳ stage 4/7 (57.14%). 1 case with severe complication-spinal injury. CONCLUSION: To treat primary hypervascular NSCLC with simple embolization of emulsion of chemotherapeutics and iodized oil is very useful and can avoid the side effect of chemotherapeutics. The key point to avoid spinal injury and other severe complications is to distinguish the spinal aretery and intratumor AV fistula by using superselective incubation with microcatheter under DSA. 中国肺癌杂志编辑部 2010-05-20 /pmc/articles/PMC6000702/ /pubmed/20677656 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.05.29 Text en 版权所有©《中国肺癌杂志》编辑部2010 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床经验
经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
title 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
title_full 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
title_fullStr 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
title_full_unstemmed 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
title_short 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
title_sort 经微导管碘化油化疗药乳剂栓塞治疗原发性富血型非小细胞肺癌41例分析
topic 临床经验
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000702/
https://www.ncbi.nlm.nih.gov/pubmed/20677656
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.05.29
work_keys_str_mv AT jīngwēidǎoguǎndiǎnhuàyóuhuàliáoyàorǔjìshuānsāizhìliáoyuánfāxìngfùxuèxíngfēixiǎoxìbāofèiái41lìfēnxī
AT jīngwēidǎoguǎndiǎnhuàyóuhuàliáoyàorǔjìshuānsāizhìliáoyuánfāxìngfùxuèxíngfēixiǎoxìbāofèiái41lìfēnxī
AT jīngwēidǎoguǎndiǎnhuàyóuhuàliáoyàorǔjìshuānsāizhìliáoyuánfāxìngfùxuèxíngfēixiǎoxìbāofèiái41lìfēnxī
AT jīngwēidǎoguǎndiǎnhuàyóuhuàliáoyàorǔjìshuānsāizhìliáoyuánfāxìngfùxuèxíngfēixiǎoxìbāofèiái41lìfēnxī
AT jīngwēidǎoguǎndiǎnhuàyóuhuàliáoyàorǔjìshuānsāizhìliáoyuánfāxìngfùxuèxíngfēixiǎoxìbāofèiái41lìfēnxī
AT jīngwēidǎoguǎndiǎnhuàyóuhuàliáoyàorǔjìshuānsāizhìliáoyuánfāxìngfùxuèxíngfēixiǎoxìbāofèiái41lìfēnxī